| Document |
Document Title |
|
WO/2019/243528A1 |
The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of ...
|
|
WO/2019/246085A1 |
Provided herein are deuterated RUC-4 compounds, and related compositions and therapeutic methods.
|
|
WO/2019/243216A1 |
The present invention relates to a liquid crystalline medium comprising dichroitic dyes made of benzothiadiazoles and related extended heterocyclic derivatives, the use of said medium for optical, electro-optical and electronic purposes,...
|
|
WO/2019/241292A1 |
Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.
|
|
WO/2019/238616A1 |
The present invention relates to compounds of formula (I), ab (I), wherein R1 to R3 and L are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds a...
|
|
WO/2019/240676A2 |
Invention relates to a coronary plaque liquefaction/cleaning catheter (A) capable of reaching all coronary arteries (1) in three dimensions and 360 degrees effective for use in atherosclerotic vascular diseases.
|
|
WO/2019/233941A1 |
The present invention relates to compounds of formula (I), wherein R1 to R6, m and n are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and me...
|
|
WO/2019/234243A1 |
The present invention relates to novel compounds that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity of a group of disorders and abnormalities associated with alpha-synuclein (α-synucl...
|
|
WO/2019/229250A1 |
The invention relates to a compound of the formula (I) as novel inhibitorof N- acylphosphatidylethanolamine phospholipase D (NAPE-PLD), and to use thereof for the prophylaxis ortreatment ofdiseases associated with NAPE-PLD. (I) wherein i...
|
|
WO/2019/232110A1 |
The present invention concerns methods for treating high-risk basal cell carcinoma (BCC) or high-risk basal cell carcinoma nevus syndrome (BCCNS) in a subject, comprising administering a composition comprising an azole inhibitor of the H...
|
|
WO/2019/229464A1 |
There are described compounds of formula (I): (I) and their use as a medicament in the treatment of diseases associated with the abnormal or elevated catabolism of tryptophan, such as, cancer, immunosuppression, viral infection, depressi...
|
|
WO/2019/223721A1 |
The present invention provides a novel aromatic heterocyclic compound serving as an ATX (Autotaxin) inhibitor, a pharmaceutical composition containing the compound, and a use of the compound and the composition in treating a disease havi...
|
|
WO/2019/223408A1 |
Disclosed by the present invention are a sulfur-containing polycyclic-hydroxypyridone carboxamide analog against HIV and an application thereof. The sulfur-containing polycyclic-hydroxypyridone carboxamide analog has a compound shown in ...
|
|
WO/2019/219771A1 |
There is provided a process for the preparation of a compound of formula I, wherein R1 and R2 each have the meanings provided in the description. There is also provided a process for the preparation of pharmaceutically-active compounds c...
|
|
WO/2019/222112A1 |
The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
|
|
WO/2019/218956A1 |
The invention falls within the technical field of chemical medicine. Specifically provided are a series of compounds acting as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation, and a medical use thereof.
|
|
WO/2019/215062A1 |
The present invention relates to 1-imidazothiadiazolo-2H-pyrrol-5-one derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. (l)
|
|
WO/2019/217509A1 |
The present invention relates to the field of anti-cancer compounds. More particularly, the invention relates to a family of benzothiazolyi urea or thiorurea compound useful as such agents. The present invention also relates to methods f...
|
|
WO/2019/217691A1 |
Provided herein are KRAS G12C inhibitors of the general formula (I) and pharmaceutical compositions comprising the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
|
|
WO/2019/212927A1 |
The present disclosure relates to compounds of formula I that are useful as modulators of 7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly diso...
|
|
WO/2019/210786A1 |
An oxazine compound and an application thereof. The oxazine compound has a structure of the general formula F. The oxazine compound described in the present invention is a kind of photo/acoustic dynamic active organic molecule with near-...
|
|
WO/2019/208635A1 |
Provided are: a compound having a xanthine oxidase inhibitory activity, represented by general formula (I) (in the formula: R1 is a group or an atom selected from a hydrogen atom, a C1-C8 alkyl group, a C1-C8 alkyl group substituted with...
|
|
WO/2019/209896A1 |
The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as ...
|
|
WO/2019/206237A1 |
The present invention provides an aminopyrimidine derivative for preventing and treating a disease associated with IDH mutation, the preparation method thereof, and the use thereof. In particular, the present invention provides a compoun...
|
|
WO/2019/200120A1 |
The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.
|
|
WO/2019/197842A1 |
The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity Formula (I) wherein X1, X2, R1, R2, R30, R31 and Ring A are each as defined herein. The present invention also relat...
|
|
WO/2019/197659A1 |
The invention relates to a compound of formula (I): and its use as drug, in particular for use in prevention and/or treatment of disease- associated bone loss, preferably selected in the group consisting of bone metastases, multiple myel...
|
|
WO/2019/191896A1 |
Provided are compounds of formula (I-1) -(I-4),which can be used as FLT3 inhibitors and for treatment and/or prevention of tumors.
|
|
WO/2019/189555A1 |
Provided is a compound that can have a CDK12-inhibiting effect and that is expected to be useful as a preventive or therapeutic drug for cancer and the like. The compound or salt thereof is represented by formula (I) (where each symbol i...
|
|
WO/2019/186384A2 |
Novel heterocyclic systems are herein disclosed, which possess many biological activities, including but not limited to anticancer activity. The disclosed compounds are useful in the treatment of many disease states related to cell proli...
|
|
WO/2019/185882A1 |
The invention provides compounds of the formula (1) or salts or tautomers thereof; wherein: Q is SO or SO2; n is 1 or 2; R1 is selected from hydrogen and a non-aromatic C1-6 hydrocarbon group; R2 and R3 are independently selected from hy...
|
|
WO/2019/186387A2 |
Novel heterocyclic fused systems are disclosed herein which possess numerous biological activities, including but not limited to antibacterial activity, and usefulness to the treatment of many disease states, such as pathogenic infection...
|
|
WO/2019/191599A1 |
The invention generally relates to the field of monocarboxylate transporter inhibitors, and more particularly to new bicyclic enone carboxylate enone compounds, the synthesis and use of these compounds and their pharmaceutical compositio...
|
|
WO/2019/182960A1 |
Compounds of Formula (1) as inhibitors of protein tyrosine phosphatase SHP2 are disclosed. The pharmaceutical compositions comprising compounds of Formula 1, methods of synthesis of these compounds, methods of treatment for diseases asso...
|
|
WO/2019/165810A1 |
Disclosed is a method for preparing a thiazoloquinazolinone derivative. The invention adopts a 1-thiazolyl indole compound as a starting material that reacts in air to prepare the product. The raw material is easily available and widely ...
|
|
WO/2019/166206A1 |
The present invention relates to an organic material and to an electronic device comprising the organic material, particularly to an electroluminescent device, particularly to an organic light emitting diode (OLED), wherein the semicondu...
|
|
WO/2019/165073A1 |
The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further ...
|
|
WO/2019/161078A1 |
Compounds of Formula (I), pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treat...
|
|
WO/2019/158550A1 |
The present invention relates to a method for preparing tert-butyl N- ((1R,2S,5S)-2-((2-((5-chloropyridin-2-yl)amino)-2-oxoacetyl)
amino) -5-(dimethylcarbamoyl)cyclohexyl)carbamate of formula (I), or a salt or solvate thereof,characteriz...
|
|
WO/2019/158731A1 |
The invention relates to 6,5 heterobicyclic ring derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use for the treatment of inflammatory conditions driven by STING activation,...
|
|
WO/2019/156987A1 |
Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae: (I) wherein the letters and sym...
|
|
WO/2019/149205A1 |
The present invention relates to a benzoheteroaryl derivative and a preparation method and medical application thereof. In particular, the present invention relates to a novel benzoheteroaryl derivative represented by general formula (I)...
|
|
WO/2019/146739A1 |
Provided is a novel compound which has D3 receptor antagonism. A compound represented by formula (IA)' (wherein: A represents S or O; R1a represents optionally substituted alkyloxy, etc.; R2a to R2d independently represent a hydrogen ato...
|
|
WO/2019/141980A1 |
The present invention relates to picolinic acid derivatives that are useful in treating fungal diseases ofplants.
|
|
WO/2019/138107A1 |
The present invention relates to compounds of Formula (I) inhibiting indoleamine 2,3-dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) enzymes. Further, their synthesis and their use as medicaments in inter alia the treatment of ...
|
|
WO/2019/130274A1 |
An electro-optic cell for an electrochromic device includes an electrochromic medium including an electrochromic compound M having at least one reduced state and at least one oxidized state. The electrochromic compound M can act as both ...
|
|
WO/2019/129025A1 |
The present invention discloses a tetrahydropyrrole compound, a preparation method therefor, a pharmaceutical composition containing the same, and a use thereof. The tetrahydropyrrole compound of the present invention is represented by g...
|
|
WO/2019/133634A1 |
The present disclosure relates to chemical compounds that modulate pantothenate kinase (PanK) activity for the treatment of metabolic disorders (such as diabetes mellitus type II), neurologic disorders (such as pantothenate kinase-associ...
|
|
WO/2019/126731A1 |
The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: (I) where A, B, R1, X1, X2, and W are described ...
|
|
WO/2019/126253A1 |
Disclosed are compounds of Formula (I) or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmace...
|
